Antiepileptic drug hypersensitivity syndrome

Area of Science:

• Pharmacology
• Immunology
• Toxicology

Background:

• Antiepileptic drug hypersensitivity syndrome (AHS) is a severe adverse drug reaction.
• It is primarily associated with aromatic antiepileptic drugs (AEDs) like phenytoin (PHT), carbamazepine (CBZ), and phenobarbital (PB).
• AHS presents with fever, rash, and internal organ involvement, potentially mimicking infections or autoimmune disorders.

Purpose of the Study:

• To define the clinical and etiological characteristics of antiepileptic drug hypersensitivity syndrome.
• To highlight diagnostic challenges and the underlying mechanisms of AHS.
• To inform clinicians about the incidence and cross-reactivity patterns of AHS.

Main Methods:

• Review of clinical presentations and laboratory findings in AHS patients.
• Analysis of the association between AEDs and oxidative metabolite formation.
• Examination of cross-reactivity data among different aromatic AEDs.

Main Results:

• AHS incidence is approximately 1 in 3,000 exposures, typically manifesting 2-8 weeks after AED initiation.
• Key symptoms include fever, rash, lymphadenopathy, and internal organ damage (e.g., hepatitis, nephritis, agranulocytosis).
• High cross-reactivity (70-80%) exists among PHT, CBZ, and PB, suggesting a common mechanism involving reactive oxidative metabolites.

Conclusions:

• AHS is a serious hypersensitivity reaction to aromatic AEDs, characterized by a distinct clinical triad.
• The syndrome's pathogenesis may involve the accumulation of toxic oxidative metabolites leading to immune-mediated cell damage.
• Awareness of AHS and its cross-reactivity is crucial for accurate diagnosis and patient management.